These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 30001247)

  • 1. Differences in antiretroviral regimens do not impact safety or level of latency reversal in persons receiving romidepsin.
    Jørgensen S; Leth S; Sommerfelt M; Østergaard L; Tolstrup M; Søgaard OS
    AIDS; 2018 Jul; 32(12):1729-1731. PubMed ID: 30001247
    [No Abstract]   [Full Text] [Related]  

  • 2. The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo.
    Søgaard OS; Graversen ME; Leth S; Olesen R; Brinkmann CR; Nissen SK; Kjaer AS; Schleimann MH; Denton PW; Hey-Cunningham WJ; Koelsch KK; Pantaleo G; Krogsgaard K; Sommerfelt M; Fromentin R; Chomont N; Rasmussen TA; Østergaard L; Tolstrup M
    PLoS Pathog; 2015 Sep; 11(9):e1005142. PubMed ID: 26379282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preconception antiretroviral therapy and birth defects: what is needed?
    Bulterys M; Berry RJ; Watts DH
    AIDS; 2014 Nov; 28(18):2777-80. PubMed ID: 25493603
    [No Abstract]   [Full Text] [Related]  

  • 4. Characterization of the HIV-1 transcription profile after romidepsin administration in ART-suppressed individuals.
    Moron-Lopez S; Kim P; Søgaard OS; Tolstrup M; Wong JK; Yukl SA
    AIDS; 2019 Mar; 33(3):425-431. PubMed ID: 30531314
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between atazanavir plasma levels and renal function in HIV-positive individuals on antiretroviral therapy with undetectable viral load.
    Luz AJ; Poeta J; Linden R; Antunes MV; Caminha LI; Callegari-Jacques SM; Sprinz E
    Int J Antimicrob Agents; 2013 May; 41(5):497-8. PubMed ID: 23453620
    [No Abstract]   [Full Text] [Related]  

  • 6. Beginning antiretroviral therapy for patients with HIV.
    Johnson JA; Sax PE
    Infect Dis Clin North Am; 2014 Sep; 28(3):421-38. PubMed ID: 25151564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined effect of Vacc-4x, recombinant human granulocyte macrophage colony-stimulating factor vaccination, and romidepsin on the HIV-1 reservoir (REDUC): a single-arm, phase 1B/2A trial.
    Leth S; Schleimann MH; Nissen SK; Højen JF; Olesen R; Graversen ME; Jørgensen S; Kjær AS; Denton PW; Mørk A; Sommerfelt MA; Krogsgaard K; Østergaard L; Rasmussen TA; Tolstrup M; Søgaard OS
    Lancet HIV; 2016 Oct; 3(10):e463-72. PubMed ID: 27658863
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Key Principles of Antiretroviral Pharmacology.
    Dionne B
    Infect Dis Clin North Am; 2019 Sep; 33(3):787-805. PubMed ID: 31395145
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Simplification of the antiretroviral regimens. A need to guarantee the long-term control of HIV infection].
    Barreiro García P; Soriano Vázquez V
    Rev Clin Esp; 2004 Apr; 204(4):212-4. PubMed ID: 15104931
    [No Abstract]   [Full Text] [Related]  

  • 10. Aggressive worsening of Sézary syndrome during early antiretroviral therapy.
    Lehloenya RJ; Shebe K; Hlela C; Dlamini S; Mankahla A; Lapiner V; Meintjes G; Todd G
    AIDS; 2013 Mar; 27(6):1035-1036. PubMed ID: 23698068
    [No Abstract]   [Full Text] [Related]  

  • 11. What is the risk of major congenital abnormalities among women on antiretroviral therapy?
    Zash RM; Williams P; Holmes LB
    AIDS; 2018 Jan; 32(3):403-404. PubMed ID: 29309347
    [No Abstract]   [Full Text] [Related]  

  • 12. Antiretroviral reduction: is it time to rethink the unthinkable?
    Colasanti J; Marconi VC; Taiwo B
    AIDS; 2014 Apr; 28(7):943-7. PubMed ID: 24401641
    [No Abstract]   [Full Text] [Related]  

  • 13. HIV, highly active antiretroviral therapy and the heart: a cellular to epidemiological review.
    Lambert CT; Sandesara PB; Hirsh B; Shaw LJ; Lewis W; Quyyumi AA; Schinazi RF; Post WS; Sperling L
    HIV Med; 2016 Jun; 17(6):411-24. PubMed ID: 26611380
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment interruption in HIV therapy: a SMART strategy?
    Jülg B; Goebel FD
    Infection; 2006 Jun; 34(3):186-8. PubMed ID: 16804667
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New antiretroviral drugs and approaches to HIV treatment.
    Paredes R; Clotet B
    AIDS; 2003; 17 Suppl 4():S85-96. PubMed ID: 15080184
    [No Abstract]   [Full Text] [Related]  

  • 16. Romidepsin-induced HIV-1 viremia during effective antiretroviral therapy contains identical viral sequences with few deleterious mutations.
    Winckelmann A; Barton K; Hiener B; Schlub TE; Shao W; Rasmussen TA; Østergaard L; Søgaard OS; Tolstrup M; Palmer S
    AIDS; 2017 Mar; 31(6):771-779. PubMed ID: 28272134
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiretroviral drug use during pregnancy and risk of premature delivery: is there a connection?
    Kourtis AP
    J Infect Dis; 2010 Apr; 201(7):978-80. PubMed ID: 20196653
    [No Abstract]   [Full Text] [Related]  

  • 18. Efficacy and safety of three second-line antiretroviral regimens in HIV-infected patients in Africa.
    Ciaffi L; Koulla-Shiro S; Sawadogo A; le Moing V; Eymard-Duvernay S; Izard S; Kouanfack C; Ngom Gueye NF; Fobang AA; Reynes J; Calmy A; Delaporte E;
    AIDS; 2015 Jul; 29(12):1473-81. PubMed ID: 26244387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Inappropriate combinations of antiretroviral drugs].
    Machala L; Cerný R
    Klin Mikrobiol Infekc Lek; 2004 Oct; 10(5):241-3. PubMed ID: 15558454
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lopinavir/ritonavir combined with raltegravir or tenofovir/emtricitabine in antiretroviral-naive subjects: 96-week results of the PROGRESS study.
    Reynes J; Trinh R; Pulido F; Soto-Malave R; Gathe J; Qaqish R; Tian M; Fredrick L; Podsadecki T; Norton M; Nilius A
    AIDS Res Hum Retroviruses; 2013 Feb; 29(2):256-65. PubMed ID: 22730929
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.